INTERNATIONAL NEWS - Roche said the FDA had approved the test helping doctors understand the genetic profile of patients’ tumors to enable better-targeted therapies and clinical tests.
“The approval of FoundationOne CDx represents a major advance in the personalisation of cancer care, facilitating access for patients in the US to a comprehensive pan-tumour companion diagnostic that will help identify approved treatment options based on the molecular footprint of each individual’s cancer,” said Roche’s Chief Medical Officer Sandra Horning, also the firm’s head of global product development.
